Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach

For patients with Hodgkin Lymphoma (HL) who experience relapse post allogeneic stem cell transplantation, limited treatment options exist, and the ultimate outcome is poor. Recently, the programmed cell death protein-1 (PD-1) inhibitors have shown remarkable efficacy in patients with refractory/rela...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Hematol Rep
Hlavní autoři: Kaloyannidis, Panayotis, Al Shaibani, Eshrak, Moinnudin, Asif, Al Anezi, Khalid, Al Hashmi, Hani
Médium: Artigo
Jazyk:Inglês
Vydáno: PAGEPress Publications, Pavia, Italy 2021
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7967268/
https://ncbi.nlm.nih.gov/pubmed/33747411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4081/hr.2021.8780
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky